Hospira Inc (HSP.N)

HSP.N on New York Stock Exchange

42.03USD
1 Aug 2013
Price Change (% chg)

$1.33 (+3.27%)
Prev Close
$40.70
Open
$41.05
Day's High
$42.60
Day's Low
$41.03
Volume
411,379
Avg. Vol
238,445
52-wk High
$42.60
52-wk Low
$28.63

HSP.N

Chart for HSP.N

About

Hospira, Inc. (Hospira) is a provider of injectable drugs and infusion technologies. Hospira's portfolio includes generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management products. Hospira's portfolio of products is used by hospitals and alternate site providers, such as... (more)

Overall

Beta: 0.87
Market Cap (Mil.): $6,741.92
Shares Outstanding (Mil.): 165.65
Dividend: --
Yield (%): --

Financials

  HSP.N Industry Sector
P/E (TTM): -- 37.93 37.76
EPS (TTM): -0.22 -- --
ROI: -1.29 19.48 18.76
ROE: -1.24 20.17 19.59
Search Stocks

UPDATE 2-Regulators pave way for biosimilar drug breakthrough

LONDON/ZURICH June 28 - European regulators have cleared the way for the first serious threat to the makers of multibillion-dollar biotechnology drugs to treat diseases such as cancer and rheumatoid arthritis.

28 Jun 2013

FDA raises drug safety concerns at Hospira facility in India

May 30 - Hospira Inc said it received a warning letter from the U.S. Food and Drug Administration raising concerns about contamination of drugs manufactured at its facility in India.

30 May 2013

U.S. court ruling favors Cubist in patent case versus Hospira

- A federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc .

20 May 2013

U.S. court ruling favors Cubist in patent case vs Hospira

May 20 - A U.S. federal court on Monday ruled in favor of Cubist Pharmaceuticals Inc on the interpretation of patent language in a case involving a generic challenge to its lead drug Cubicin by Hospira Inc.

20 May 2013

FDA flags new concerns on Hospira's Rocky Mount plant

- Hospira Inc said U.S. health regulators raised fresh concerns about the injectable-drugs maker's troubled Rocky Mount, North Carolina manufacturing plant - one of its largest production facilities.

05 Mar 2013

Hospira withdraws outlook on FDA import ban, shares fall

- Injectable-drugs maker Hospira Inc withdrew the 2013 profit and revenue outlook it gave on Wednesday after the U.S. health regulator imposed an import ban on some of its products.

14 Feb 2013

Hospira gets FDA notice over medical device problems

- Hospira Inc, a hospital products maker that has grappled with regulatory issues at manufacturing plants for the past 18 months, said it had received a notice over the quality of its medical devices from the U.S. Food and Drug Administration.

13 Feb 2013

UPDATE 3-Hospira gets FDA notice over medical device problems

* Expects 2013 sales up 1 pct to 3 pct, adjusted diluted eps of $2.05-$2.20

13 Feb 2013

Hospira swings to profit in fourth quarter as sales rise

Feb 13 - Injectable drug provider Hospira Inc on Wednesday reported a profit for the fourth quarter versus a year-earlier loss as its sales increased more than 8 percent.

13 Feb 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$58.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$495.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks